Society for Endocrinology - a world-leading authority on hormones

Postmenopausal osteoporosis phase 3 trial starts, say Amgen and UCB (Medical News Today, 9 April 2012)

10 Apr 2012


UCB and Amgen have announced the development of a phase 3 clinical trial program of their experimental sclerostin antibody (CDP7851/AMG 785) for the treatment of postmenopausal osteoporosis.

Full article